Patents by Inventor Haihui Yu

Haihui Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders
    Publication number: 20150315152
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound 1 in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: November 26, 2014
    Publication date: November 5, 2015
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Haihui Yu, Beth Jennifer Hoffman
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISORDERS
    Publication number: 20150080431
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound 1 in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 19, 2015
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Haihui Yu, Beth Jennifer Hoffman
  • Pharmaceutical Compositions and Administrations Thereof
    Publication number: 20140336219
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: October 16, 2013
    Publication date: November 13, 2014
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Chien-Jung Huang, Paul Adrian Negulescu, Haihui Yu
  • PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
    Publication number: 20140323521
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: May 2, 2014
    Publication date: October 30, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Chien-Jung Huang, Paul Adrian Negulescu, Haihui Yu
  • PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
    Publication number: 20140142138
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: October 16, 2013
    Publication date: May 22, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Chien-Jung Huang, Paul Adrian Negulescu, Haihui Yu
  • Pharmaceutical Compositions and Administrations Thereof
    Publication number: 20130331412
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: November 19, 2012
    Publication date: December 12, 2013
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Chien-Jung Huang, Paul Adrian Negulescu, Haihui Yu
  • Pharmaceutical Compositions and Administrations Thereof
    Publication number: 20110288122
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 24, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Chien-Jung Huang, Paul Adrian Negulescu, Haihui Yu